California-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) and MiroBio, has agreed to acquire UK-based clinical-stage biotechnology company MiroBio for approximately USD 405m in cash, the company said.
Under the terms of the agreement, Gilead will acquire all of the outstanding share capital of MiroBio.
The acquisition will provide Gilead with MiroBio's proprietary discovery platform and its entire portfolio of immune inhibitory receptor agonists.
Cowen is acting as financial advisor to Gilead. Centerview Partners is acting as financial advisor to MiroBio.
Davis Polk and Wardwell LLP, Mayer Brown LLP, and Mishcon de Reya LLP are serving as legal counsel to Gilead, and Goodwin Procter LLP and Wilson Sonsini Goodrich and Rosati are serving as legal counsel to MiroBio.
MiroBio is a private biotechnology company whose mission is to develop a new class of therapeutic agents, checkpoint agonist antibodies, to restore immune balance in autoimmune patients.
MiroBio is backed by international investors including Oxford Science Enterprises, Samsara BioCapital, SR One, Medicxi, Advent Life Sciences, OrbiMed and Monograph.
OneWater Marine Closes USD 125m Acquisition of Marine Industry Supplier Ocean Bio-Chem
MTY Food Group to Acquire Restaurant Operator BBQ Holdings for USD 200m
Devon Energy to Acquire Eagle Ford Operator Validus Energy
Eagle Pharmaceuticals Takes Equity Stake in Enalare Therapeutics
Energy Services of America Business Acquires Assets from Ryan Environmental
ODL Acquires Canadian Insulated Glass Maker Robover
Anchor Peabody Represents Foxworth-Galbraith in Acquisition by USLBM Holdings
Coca-Cola HBC to Acquire Three Cents Beverage Mixer Line
Supreme Acquires Assets of Vaping Maker Cuts Ice and E-Liquids Developer Flavour Core
NinjaCat Acquires Budget Management Software Suite Shape.io
Wagepoint Acquires HR Software Firm KinHR
Curaleaf to Acquire Majority Stake in Germany´s Four 20 Pharma
Threecolts Acquires Amazon Seller Email and Review Automation Tool FeedbackWhiz
Earthstone Energy Closes USD 627m Acquisition of New Mexico Assets of Titus